Raxatrigine - 99%, high purity , Sodium channel protein type IX alpha subunit blocker, CAS No.934240-30-9, Sodium channel protein type IX alpha subunit blocker

Item Number

R649384

• Synonyms: N-{2-oxo-2-[(3S)-3-{[(1s,4s)-4-hydroxy-4-[5-(pyrimidin-2-yl)pyridin-2-yl]cyclohexyl]amino}pyrrolidin-1-yl]ethyl}-3-(trifluoromethyl)benzamide | DB11706 | 2,6-Nonadienoic acid, 7-ethyl-9-[(2R,3S)-3-ethyl-3-methyloxiranyl]-3-methyl-, methyl ester, (2E,6E)-
• Specifications & Purity: ≥99%
• Biochemical and Physiological Mechanisms: Raxatrigine (GSK-1014802) is a novel small molecule state-dependent sodium channel blocker; Nav1.7 sodium channel inhibitor .
• Storage Temp: Store at -20°C
• Shipped In: Ice chest + Ice pads
• Action Type: BLOCKER
• Mechanism of action: Sodium channel protein type IX alpha subunit blocker

Product Description

Raxatrigine (GSK-1014802) is a novel small molecule state-dependent sodium channel blocker; Nav1.7 sodium channel inhibitor .

In Vitro

Like lamotrigine, both GSK2 and GSK3 were able to prevent the deficit in reversal learning produced by PCP, thus confirming their potential in the treatment of cognitive symptoms of schizophrenia. However, higher doses than those required for anticonvulsant efficacy of the drugs were needed for activity in the reversal-learning model, suggesting a lower therapeutic window relative to mechanism-dependent central side effects for this indication. Raxatrigine (GSK-1014802) received orphan-drug designation from the US Food and Drug Administration in July 2013. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Form:Solid

IC50& Target:Sodium channel blocker